Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zevalin Price Negotiations Will Be Model For Medicare Part B, Scully Says

Executive Summary

Idec's experience securing Medicare reimbursement for Zevalin should be considered the model for how coverage decisions will work for new products once Part B payment reforms are implemented in 2005, former CMS Administrator Tom Scully said

You may also be interested in...



Zevalin, Bexxar Off-Label Coverage Decision Affirms Status Quo

Medicare contractors will retain the discretion to determine when to cover Biogen Idec's Zevalin and GlaxoSmithKline's Bexxar for off-label use in non-Hodgkin's lymphoma under a proposed coverage determination issued by the Centers for Medicare & Medicaid Services May 4

Zevalin, Bexxar Off-Label Coverage Decision Affirms Status Quo

Medicare contractors will retain the discretion to determine when to cover Biogen Idec's Zevalin and GlaxoSmithKline's Bexxar for off-label use in non-Hodgkin's lymphoma under a proposed coverage determination issued by the Centers for Medicare & Medicaid Services May 4

Cancer Drugs Will Continue To Command High Prices, Scully Predicts

The transformation in the Medicare market will not prevent cancer drugs from commanding very high prices, former Centers for Medicare & Medicaid Services Administrator Tom Scully predicted during the Washington Research Group's annual symposium Nov. 5

Related Content

UsernamePublicRestriction

Register

PS043191

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel